PRE-MDA SCREENING FOR TREATMENT ELIGIBILITY DURING COMMUNITY-WIDE TREATMENT

1. PURPOSE
Screening is the process by which community drug distributors and/or field officers determine whether an individual is eligible to receive albendazole preventive chemotherapy during community-wide mass drug administration (MDA).

2. INTENDED AUDIENCE
MDA drug distributors and accompanying personnel such as field officers.

3. RESPONSIBILITIES
All DeWorm3 study staff should understand and follow this SOP during MDA in all intervention clusters where community-wide MDA with albendazole is being conducted. It is the responsibility of the site’s Principal Investigator and Trial Coordinator to ensure that all study staff and community volunteers comply with this SOP.

4. DEFINITIONS
4.1. SurveyCTO Treatment Log: A SurveyCTO treatment log form programmed on smartphones, to be used by field officers accompanying community drug distributors (CDDs) during community-wide MDA. This log will be used to identify households and individuals to be treated in the intervention clusters and used to record if an individual is treated, refuses treatment, not present for treatment, or ineligible for treatment based on pre-MDA screening criteria.

4.2. Household Treatment List: A paper-based list of households listed by cluster and village, providing household location, household head name, household ID, household phone number (if available) and number of household members. This will be used by the CDDs to locate the households plan the route when treating.

5. REQUIRED MATERIALS
5.1 SurveyCTO Treatment Log on smartphone
5.2 Household Treatment List
5.3 Albendazole Supply

6. PROCEDURE
6.1. Prior treatment
a. Upon initial encounter with an individual during community-wide MDA, CDDs and/or field officers should ask and confirm that the individual has not been recently treated (i.e. they have not been treated with albendazole in the previous two weeks).

b. This treatment may have been:
   i. At the school during the school-targeted treatment campaign
   ii. In a health facility during a routine or ante natal clinic visit
   iii. By self-medication.

c. If the individual reports having been treated in the last two weeks, record where/how they were treated.

d. For children treated at school in the last two weeks, select how this was confirmed, either by observing an inked finger, reported by guardian or reported by child themselves.
6.2. Age
   a. Drug distributors should confirm that the untreated individual is older than 12 months of age.
   b. If the individual is less than 12 months of age they are not eligible for treatment and this should be indicated in the SurveyCTO Treatment Log.
   c. If the child is between 12 and 24 months, half a tablet should be crushed and administered in solution with clean, safe water.

6.3. History of adverse events
   a. If the individual has a history of an adverse reaction to a benzimidazole (albendazole or mebendazole) or if the person reports an adverse reaction to an unknown drug used for deworming, they are not eligible for treatment.
   b. If the individual is unsure if they have been treated with benzimidazoles previously, proceed with treatment.

6.4. Pregnancy
   a. The drug distributor should confirm that any female above the age of 11 years is not in their first trimester of pregnancy. Ask if they know if they are pregnant, and if so, how far along.
   b. A female in the first 12 weeks of her pregnancy is not eligible for treatment and this should be recorded in the SurveyCTO Treatment Log.

6.5. Severe illness
   a. Individuals who are severely ill are not eligible for treatment.
   b. Severe illness is defined as any acute condition that the drug distributor feels warrants medical consultation.

6.6. Intoxication
   a. Individuals who are intoxicated with drugs or alcohol are not eligible for treatment, as they cannot participate in the informed consent process.
   b. A return visit should be made to treat them when they are no longer intoxicated.

6.7. Other conditions to consider
   a. Women who are breastfeeding are eligible for treatment, in accordance with WHO guidelines.
   b. HIV-infected individuals are eligible for treatment, regardless of whether or not they are taking antiretrovirals (ARV medications) are eligible for treatment.
   c. Individuals with managed chronic infections (i.e. diabetes) are eligible for treatment.
   d. Individuals with history of epilepsy are eligible for treatment.
Figure 1: Summary of screening cascade

Untreated individual

- Age <12 months
  - History of adverse reaction to benzimidazoles
    - Intoxicated
      - Seriously ill
        - Male
          - Proceed with treatment
        - Female
          - Proceed with treatment
    - No history of adverse reaction to benzimidazoles
      - Not intoxicated
        - Not seriously ill
          - Female not pregnant
            - Proceed with treatment
          - Female pregnant
            - In first 12 weeks of pregnancy
            - Proceed with treatment
          - Past 12 weeks of pregnancy
            - Do not treat

- Age ≥12 months
  - History of adverse reaction to benzimidazoles
    - Intoxicated
      - Proceed with treatment
    - No history of adverse reaction to benzimidazoles
      - Not intoxicated
        - Not seriously ill
          - Proceed with treatment

Proceed with treatment
Do not treat
<table>
<thead>
<tr>
<th>Date</th>
<th>Name</th>
<th>Title</th>
<th>Signature*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*By signing this log, study staff confirm that they have read and understood the content of the SOP*